Clinical Trials Logo

Wet Macular Degeneration clinical trials

View clinical trials related to Wet Macular Degeneration.

Filter by:

NCT ID: NCT04047472 Completed - Clinical trials for Neovascular Age-Related Macular Degeneration

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration

Start date: November 29, 2019
Phase: Phase 3
Study type: Interventional

To compare brolucizumab to aflibercept in Chinese patients with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)

NCT ID: NCT03958461 Completed - Periodontitis Clinical Trials

Connection Between Periodontitis and Exudative Age-related Macular Degeneration

FLAREPARO
Start date: January 1, 2020
Phase: N/A
Study type: Interventional

Aqueous flare is increased in different kind of inflammations of eye. This is caused by disruption of blood-aqueous-barrier. The investigators assume that low grade systemic inflammation, such as periodontitis, increase aqueous flare and possibly activates exudative age-related macular degeneration.

NCT ID: NCT03954626 Completed - Clinical trials for Age-Related Macular Degeneration

Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD

Start date: June 7, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study was to collect ECG data after a single IVT injection of brolucizumab 6 mg in patients with neovascular age-related macular degeneration (nAMD).

NCT ID: NCT03939195 Completed - Clinical trials for Macular Degeneration Exudative Eye Right

OCTA (Optical Coherence Angiography Tomography) Versus Structural OCT(Optical Coherence Tomography) in Neovascular AMD (Age Macular Degeneration)

QUAOBARE
Start date: December 1, 2018
Phase:
Study type: Observational

The objective is to find if there is a relationship between the Fractal Dimension, the gap, vascular density (VD), the surface, the span ratio and the status of the choroidal neovessels to adjust the interval between 2 intravitreal injections nor on the qualitative aspect of Optical Coherence Structural Tomography but also on quantified quantitative and objective values.

NCT ID: NCT03930641 Completed - Clinical trials for Neovascular Age Related Macular Degeneration

Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration

Start date: May 23, 2019
Phase: Phase 3
Study type: Interventional

This was a multicenter, open label study that is designed to evaluate the safety of brolucizumab 6 mg in a prefilled syringe in subjects with neovascular age related macular degeneration and to support collection of observations of the prefilled syringe use for intravitreal injection.

NCT ID: NCT03909425 Completed - Clinical trials for Neovascular Age-related Macular Degeneration

Defining Disease Activity in Neovascular AMD With Optical Coherence Tomography Angiography

DANA
Start date: September 2, 2019
Phase:
Study type: Observational

The purpose of this study is to be able to describe optical coherence angiography (OCTA) patterns of disease activity and quiescence in eyes that have received treatment. The target population group is patients that have neovascular age-related macular degeneration and have had treatment with aflibercept for this condition. This is a single-site study and does not involve any masking or treatment allocation.

NCT ID: NCT03861234 Completed - Clinical trials for Wet Macular Degeneration

A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)

Start date: June 27, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a study in people with an eye disease called wet age-related macular degeneration (wAMD). The purpose of the study is to find out how well different doses of a medicine called BI 836880 are tolerated. People can participate if they are at least 55 years old and if they have new blood vessels in their eyes despite treatment (anti-VEGF therapies). The study has 2 parts. In the first part, people get only 1 dose of BI 836880. This part takes 6 weeks. In the second part, people get 3 times the same dose of BI 836880. This part takes 6 months. BI 836880 is injected into the eye. During the entire study doctors regularly check the health of the participants.

NCT ID: NCT03844074 Completed - Clinical trials for Age-related Macular Degeneration

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Start date: October 1, 2018
Phase: Phase 3
Study type: Interventional

This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.

NCT ID: NCT03835884 Completed - Clinical trials for Diabetic Macular Edema

A Study Assessing AR-13503 Implant in Subjects With nAMD or DME

Start date: June 24, 2019
Phase: Phase 1
Study type: Interventional

First-in-Human Study of the Safety of AR-13503 Sustained Release Intravitreal Implant in Subjects with Neovascular Age-Related Macular Degeneration (nAMD) and Subjects with Diabetic Macular Edema (DME)

NCT ID: NCT03834753 Completed - Clinical trials for Age-related Macular Degeneration

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Start date: June 25, 2019
Phase: Phase 3
Study type: Interventional

This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.